Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEVOTE: Cardiovascular Safety of Insulin Degludec vs Insulin Glargine
NCT01959529Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2013
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
A Phase 3 trial of insulin degludec in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2013; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01959529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01959529.